| pubmed-article:8720288 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8720288 | lifeskim:mentions | umls-concept:C0337810 | lld:lifeskim |
| pubmed-article:8720288 | lifeskim:mentions | umls-concept:C0002199 | lld:lifeskim |
| pubmed-article:8720288 | lifeskim:mentions | umls-concept:C0035525 | lld:lifeskim |
| pubmed-article:8720288 | lifeskim:mentions | umls-concept:C0596545 | lld:lifeskim |
| pubmed-article:8720288 | lifeskim:mentions | umls-concept:C0280274 | lld:lifeskim |
| pubmed-article:8720288 | lifeskim:mentions | umls-concept:C0205195 | lld:lifeskim |
| pubmed-article:8720288 | pubmed:dateCreated | 1996-10-11 | lld:pubmed |
| pubmed-article:8720288 | pubmed:abstractText | A sustained biochemical and virologic response to standard interferon therapy for chronic hepatitis C is seen in no more than 25% of patients, and the efficacy of re-treatment or of higher doses in non-responders and relapsers has not been established. A more effective therapy for interferon alfa-resistant hepatitis C is needed. | lld:pubmed |
| pubmed-article:8720288 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8720288 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8720288 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8720288 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8720288 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8720288 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8720288 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8720288 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8720288 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8720288 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8720288 | pubmed:issn | 0168-8278 | lld:pubmed |
| pubmed-article:8720288 | pubmed:author | pubmed-author:BarbaraLL | lld:pubmed |
| pubmed-article:8720288 | pubmed:author | pubmed-author:MiglioliMM | lld:pubmed |
| pubmed-article:8720288 | pubmed:author | pubmed-author:BrillantiSS | lld:pubmed |
| pubmed-article:8720288 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8720288 | pubmed:volume | 23 Suppl 2 | lld:pubmed |
| pubmed-article:8720288 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8720288 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8720288 | pubmed:pagination | 13-5; discussion 15-6 | lld:pubmed |
| pubmed-article:8720288 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:8720288 | pubmed:meshHeading | pubmed-meshheading:8720288-... | lld:pubmed |
| pubmed-article:8720288 | pubmed:meshHeading | pubmed-meshheading:8720288-... | lld:pubmed |
| pubmed-article:8720288 | pubmed:meshHeading | pubmed-meshheading:8720288-... | lld:pubmed |
| pubmed-article:8720288 | pubmed:meshHeading | pubmed-meshheading:8720288-... | lld:pubmed |
| pubmed-article:8720288 | pubmed:meshHeading | pubmed-meshheading:8720288-... | lld:pubmed |
| pubmed-article:8720288 | pubmed:meshHeading | pubmed-meshheading:8720288-... | lld:pubmed |
| pubmed-article:8720288 | pubmed:meshHeading | pubmed-meshheading:8720288-... | lld:pubmed |
| pubmed-article:8720288 | pubmed:meshHeading | pubmed-meshheading:8720288-... | lld:pubmed |
| pubmed-article:8720288 | pubmed:meshHeading | pubmed-meshheading:8720288-... | lld:pubmed |
| pubmed-article:8720288 | pubmed:meshHeading | pubmed-meshheading:8720288-... | lld:pubmed |
| pubmed-article:8720288 | pubmed:meshHeading | pubmed-meshheading:8720288-... | lld:pubmed |
| pubmed-article:8720288 | pubmed:meshHeading | pubmed-meshheading:8720288-... | lld:pubmed |
| pubmed-article:8720288 | pubmed:meshHeading | pubmed-meshheading:8720288-... | lld:pubmed |
| pubmed-article:8720288 | pubmed:meshHeading | pubmed-meshheading:8720288-... | lld:pubmed |
| pubmed-article:8720288 | pubmed:meshHeading | pubmed-meshheading:8720288-... | lld:pubmed |
| pubmed-article:8720288 | pubmed:meshHeading | pubmed-meshheading:8720288-... | lld:pubmed |
| pubmed-article:8720288 | pubmed:meshHeading | pubmed-meshheading:8720288-... | lld:pubmed |
| pubmed-article:8720288 | pubmed:year | 1995 | lld:pubmed |
| pubmed-article:8720288 | pubmed:articleTitle | Combination antiviral therapy with ribavirin and interferon alfa in interferon alfa relapsers and non-responders: Italian experience. | lld:pubmed |
| pubmed-article:8720288 | pubmed:affiliation | Istituto di Clinica Medica e Gastroenterologia, University of Bologna, Italy. | lld:pubmed |
| pubmed-article:8720288 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8720288 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:8720288 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:8720288 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8720288 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8720288 | lld:pubmed |
